Non-Small Cell Lung Cancer Market, by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, and Large Cell Neuroendocrine Tumors), by Treatment (Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza), and Ramucirumab

Non-Small Cell Lung Cancer Market, by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, and Large Cell Neuroendocrine Tumors), by Treatment (Chemotherapy, Targeted Therapy (Bevacizumab (Avastin), Necitumumab (Portrazza), and Ramucirumab (Cyramza), Immunotherapy (Nivolumab (Opdivo), Atezolizumab (Tecentriq), and Others) , by End user ( Hospitals, Homecare, Specialty Clinics and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Lung cancer symptoms are not noticeable in its early stage as these symptoms are considered for other type of illness such as pneumonia or collapsed lung. Some symptoms of lung cancer include chest pain, harsh/raspy sound while breathing, wheezing, weight loss, continuous cough, hoarseness or voice changes, shortness of breath, lung problems such as bronchitis or pneumonia, and others. Moreover, if it spreads through the bloodstream or the lymphatics into other parts of the body then it exhibits symptoms such as bone pain, weakness in arm or leg, yellow skin, yellow eyes, headache, and seizures.

Some diagnostic tests are performed by doctors to detect lung cancer, which include diagnostic imaging tests such as X-ray, magnetic resonance imaging (MRI), ultrasound, computed tomography scan (CT scan), and also by diagnosing mucous, which the patient can cough up to check the presence of cancer cells, which is called as sputum cytology. By taking the cells of lungs from abnormal growth area of the lung or from the fluid of lungs through the procedure called as fine needle aspiration biopsy, bronchoscopy, and mediastinoscopy, lung cancer can be diagnosed.

Market Dynamics

Increasing consumption of tobacco and active engagement in passive smoking are two major factors responsible for non-small cell lung cancer, which are expected to drive market growth over the forecast period. For instance, according to data published in March 2022, on The Centers for Disease Control and Prevention (CDC), stated that nearly 40 million U.S. adults smoke cigarettes, and an estimated 2.55 million middle and high school students use at least one tobacco product, including e-cigarettes every year.

Key features of the study:

• This report provides in-depth analysis of the global non-small cell lung cancer treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global non-small cell lung cancer market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global non-small cell lung cancer treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market

Detailed Segmentation:

• Global Non-small Cell Lung Cancer Treatment Market, By Type:
• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Large Cell Neuroendocrine Tumors
• Global Non-small Cell Lung Cancer Treatment Market, By Treatment:
• Chemotherapy
• Targeted Therapy
• Bevacizumab (Avastin)
• Necitumumab (Portrazza)
• Ramucirumab (Cyramza)
• Immunotherapy
• Nivolumab (Opdivo)
• Atezolizumab (Tecentriq)
• Others
• Global Non-small Cell Lung Cancer Treatment Market, By End User:
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Global Non-small Cell Lung Cancer Treatment Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Pfizer Inc.
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• AstraZeneca plc
• Hoffmann-La Roche Ltd.
• Eli Lilly and Company,
• Boehringer Ingelheim GMBH
• Novartis AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.

“*” marked represents similar segmentation in other categories in the respective section.